Rocket Pharmaceuticals, Inc. (RCKT)

23,33 +0,35 (+1,52%) Alla chiusura: 04:00PM EDT

Rocket Pharmaceuticals, Inc.

9 Cedarbrook Drive
Cranbury, NJ 08512
United States
609 659 8001
https://www.rocketpharma.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 268

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Gaurav D. Shah M.D.	CEO & Director	1,01M	N/D	1975
Ms. Kinnari Patel M.B.A., Pharm.D.	Head of R&D, President & COO	846,11k	N/D	1979
Mr. Mayo Pujols	Chief Technical Officer	877,69k	N/D	1969
Mr. Jonathan Schwartz M.D.	Chief Medical & Gene Therapy Officer	657,87k	627,82k	1964
Mr. Aaron Ondrey	Chief Financial Officer	N/D	N/D	1977
Mr. Martin Louis Wilson J.D.	General Counsel, Chief Compliance Officer & Chief Corporate Officer	149,95k	N/D	1976
Kevin Giordano	Director of Corporate Communications	N/D	N/D	N/D
Ms. Isabel Carmona J.D.	Chief People Officer	N/D	N/D	N/D
Dr. Gayatri R. Rao J.D., M.D.	Senior VP of Clinical Safety & Chief Regulatory Officer	N/D	N/D	N/D
Mr. Raj Prabhakar M.B.A.	Chief Business Officer	619,13k	N/D	1974

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.

Governance aziendale

L'ISS Governance QualityScore di Rocket Pharmaceuticals, Inc. al 1 maggio 2024 è 8. I criteri di valutazione fondamentali sono revisione: 5; Consiglio di Amministrazione: 10; diritti degli azionisti: 6; retribuzione: 7.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.